levodopa has been researched along with rivastigmine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (88.89) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Hoefnagels, WH; Horstink, MW; Scheepmaker, AJ; Strijks, FE | 1 |
| Ludin, HP | 1 |
| Driguès, N; Sagi, Y; Youdim, MB | 1 |
| Giladi, N; Gurevich, TY; Korczyn, AD; Shabtai, H; Simon, ES | 1 |
| Damier, P; Meyniel, C | 1 |
| Blumberger, DM; Chen, R; Daskalakis, ZJ; Pollock, BG; Rajji, TK; Salavati, B; Zomorrodi, R | 1 |
2 review(s) available for levodopa and rivastigmine
| Article | Year |
|---|---|
[Are there innovations in the treatment of Parkinson's disease?].
Topics: Antiparkinson Agents; Cannabis; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dopamine Agonists; Heart Valve Diseases; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Pergolide; Phenylcarbamates; Placebos; Rivastigmine; Time Factors | 2004 |
[Lewy body dementia and Parkinson disease dementia].
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Dementia; Diagnosis, Differential; Disease Progression; Dopamine Agents; Humans; Iatrogenic Disease; Levodopa; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Parkinsonian Disorders; Phenylcarbamates; Psychotropic Drugs; Rivastigmine; Serotonin Antagonists | 2007 |
1 trial(s) available for levodopa and rivastigmine
| Article | Year |
|---|---|
Pharmacological Manipulation of Cortical Inhibition in the Dorsolateral Prefrontal Cortex.
Topics: Adult; Baclofen; Cholinesterase Inhibitors; Cross-Over Studies; Dextromethorphan; Dopamine Agents; Double-Blind Method; Electroencephalography; Excitatory Amino Acid Antagonists; Female; GABA-B Receptor Agonists; Humans; Levodopa; Male; Neural Inhibition; Prefrontal Cortex; Rivastigmine; Transcranial Magnetic Stimulation; Young Adult | 2018 |
6 other study(ies) available for levodopa and rivastigmine
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
[Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Carbamates; Cholinesterase Inhibitors; Drug Therapy, Combination; Humans; Levodopa; Lewy Body Disease; Male; Neuroprotective Agents; Olanzapine; Phenylcarbamates; Pirenzepine; Risperidone; Rivastigmine; Treatment Outcome | 2003 |
The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.
Topics: Animals; Basal Ganglia; Behavior, Animal; Carbamates; Cholinesterase Inhibitors; Dopamine; Hippocampus; Hyperkinesis; Indans; Levodopa; Lewy Body Disease; Male; Monoamine Oxidase Inhibitors; Motor Activity; Muscarinic Antagonists; Norepinephrine; Phenylcarbamates; Rats; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Serotonin; Time Factors; Tranylcypromine; Tryptophan | 2005 |
Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Drug Therapy, Combination; Female; Functional Laterality; Humans; Levodopa; Male; Mental Status Schedule; Neurologic Examination; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Rivastigmine; Tremor | 2006 |